@cgconsortium.bsky.social
Cancer Genomics Consortium (CGC) is a 501(c)3 non-profit organization whose mission is to providing high quality education and promoting best practices in clinical cancer genomics.
Join us in congratulating Katie Schieffer, PhD, FACMG who is being featured in our December #CGCspotlight! Katie is a member of the Genomic Resources Development Committee and the Genomic Diagnosis of Sarcoma Working Group. Learn more here: buff.ly/5sGAxRY
09.12.2025 15:03 β π 0 π 0 π¬ 0 π 0
We invite you to attend the monthly Collaborative Genomics Case Conference Webinar. This month's case conference webinar will include two case presentations. You can find more information here: buff.ly/w0NzXJ6
#CGCVolunteers #genomics #cancer #research #genetics #clinicaltesting #bioinformatics
Join a global community shaping the future of clinical cancer genomics. As a CGC member, youβll connect with international genomics professionals, gain access to cutting-edge educational resources, and collaborate on initiatives that advance cancer genomics worldwide. Learn more: buff.ly/tS7YP02
08.12.2025 15:03 β π 0 π 0 π¬ 0 π 0
Reminder to register for the upcoming webinar Circulating Tumor DNA as Diagnostic Tool in Oncology on December 11, 2025. Click here to register: buff.ly/lQIHd2h
#CGCVolunteers #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics #molecular
Q28. What is NOT a possible explanation for a deletion of one signal (green or orange) of a break apart probe?
A. Typical result
B. Regional deletion
C. Deletion causing fusion
D. Unbalanced rearrangement
Type your answer in the chat below and come back next week for the answer and explanation!
There has never been a more exciting time to be a professional working in the field of Cancer Genomics! CGC members have the opportunity to help shape the field as we engage in projects to improve research, resources, and clinical practice in Cancer Genomics. Learn more here: buff.ly/tS7YP02
03.12.2025 15:03 β π 0 π 0 π¬ 0 π 0
Thank you for your consideration in making a tax-deductible contribution to help us continue advancing high-quality genomic interpretation and improving patient care.
Click here to donate: buff.ly/Jzr5229
The CGC Communications Committee is chiefly responsible for the CGC website, member management system, and social media profiles, promoting awareness and visibility of the CGC. Learn more about the communications committee here: buff.ly/eW1mD4R
02.12.2025 15:03 β π 0 π 0 π¬ 0 π 0
You donβt have to waitβearly gifts are welcome and count toward our Giving Tuesday total. Together, we can strengthen the scientific community that drives precision oncology forward.
On Giving Tuesday, we hope youβll consider making a tax-deductible contribution to help us continue advancing high-quality genomic interpretation and improving patient care.
Click here to donate today: buff.ly/HKj8izN
Next week, the Cancer Genomics Consortium (CGC) will participate in Giving Tuesday, a global day of generosity, for the first time and we invite you to join us in supporting the future of cancer genomics. Learn how you can support the CGC here: buff.ly/Jzr5229
26.11.2025 20:00 β π 0 π 0 π¬ 0 π 0
Join a global community shaping the future of clinical cancer genomics. As a CGC member, youβll connect with international genomics professionals, gain access to cutting-edge educational resources, and collaborate on initiatives that advance cancer genomics worldwide. buff.ly/tS7YP02
25.11.2025 20:00 β π 0 π 0 π¬ 0 π 0
Q27. A 16 y.o. female has hypercalcemia and hyperparathyroidism and family history of pituitary gland tumor and hyperparathyroidism in father. What would be likely finding in hereditary cancer panel?
A. MEN1
B. MEN2
C. MSH3
D. RET
Reminder to register for the upcoming webinar Circulating Tumor DNA as Diagnostic Tool in Oncology on December 11, 2025. Click here to register: buff.ly/lQIHd2h
#CGCVolunteers #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics #molecular
Type your answer in the chat below and come back next week for the answer and explanation!
18.11.2025 15:02 β π 0 π 0 π¬ 0 π 0Q27. A 16 y.o. female has hypercalcemia and hyperparathyroidism and family history of pituitary gland tumor and hyperparathyroidism in father. What would be likely finding in hereditary cancer panel?
A. MEN1
B. MEN2
C. MSH3
D. RET
Q26. Which of the following abnormalities are defined as high risk in newly diagnosed patients with multiple myeloma?:
A. 1p32 gain
B. t(4;14)
C. t(11;14)
D. Trisomy 8
Join us in congratulating Ninette Cohen, PhD, FACMG who is being featured in our November #CGCspotlight! Ninette is a member of the Communications Committee where she serves as chair of the website subcommittee. Learn more here: buff.ly/5sGAxRY
#CGCVolunteers #genomics #cancer #research #genetics
Registration Now Open: The Cancer Genomics Consortium (CGC) invites you to attend Circulating Tumor DNA as Diagnostic Tool in Oncology on December 11, 2025. Click here to register: buff.ly/9E1KZio
#CGCVolunteers #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
Q26. Which of the following abnormalities are defined as high risk in newly diagnosed patients with multiple myeloma?:
A. 1p32 gain
B. t(4;14)
C. t(11;14)
D. Trisomy 8
Type your answer in the chat below and come back next week for the answer and explanation!
Mark your calendar with #CGCAnnual2026βwe look forward to seeing you in Houston next year!ο»Ώ
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics #molecular
The Education Committee is comprised of dedicated members who are committed to providing varied and interesting educational resources to our members throughout the year. We always welcome suggestions and feedback from members. Learn more about the committees here: buff.ly/q0FY6mo
#CGCVolunteers
Final Day! Help shape the program for the Cancer Genomics Consortium 2026 Annual Meeting! The Cancer Genomics Consortium is soliciting proposals for invited sessions for the 17th Annual Meeting in Houston, TX.
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics
Q25. A diffuse astrocytic glioma arising in 65-year-old patient is found to be IDH-wild type and H3-wild type, what is a defining genetic feature of glioblastoma, IDH-wild type, CNS WHO grade 4?
A. Gain of chromosome 10
B. TERT promoter mutation
C. EGFR gene amplification
D. B and C
A quick reminder to join us tomorrow for "Transforming Tumor Methylation Profiling with Oxford Nanopore Direct DNA Sequencing." Click here to learn more and register today:ο»Ώο»Ώο»Ώ buff.ly/Oxz6OQh
27.10.2025 14:06 β π 1 π 0 π¬ 0 π 0
Help shape the program for the Cancer Genomics Consortium 2026 Annual Meeting! The Cancer Genomics Consortium is soliciting proposals for invited sessions for the 17th Annual Meeting in Houston, TX.
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
Join us next week for "Transforming Tumor Methylation Profiling with Oxford Nanopore Direct DNA Sequencing" on October 28, 2025. Click here to learn more and register today:ο»Ώ buff.ly/Oxz6OQh
22.10.2025 14:04 β π 2 π 1 π¬ 0 π 0Q25. A diffuse astrocytic glioma arising in 65-year-old patient is found to be IDH-wild type and H3-wild type, what is a defining genetic feature of glioblastoma, IDH-wild type, CNS WHO grade 4?
A. Gain of chromosome 10
B. TERT promoter mutation
C. EGFR gene amplification
D. B and C
The Cancer Genomics Consortium (CGC) and Oxford Nanopore Technologies invite you to attend Transforming Tumor Methylation Profiling with Oxford Nanopore Direct DNA Sequencing on October 28, 2025. Click here to learn more and to register today: buff.ly/Oxz6OQh
16.10.2025 15:16 β π 1 π 0 π¬ 0 π 0
Join us in congratulating Teresa A. Smolarek, PhD, FACMG who is being featured in our October #CGCspotlight! Teresa is a member of the Genomic Diagnosis of Sarcoma Working Group and the Education Committee. Learn more here: buff.ly/UkJ5OXS
#CGCVolunteers #genomics #cancer #research #genetics
